Literature DB >> 33515135

Prevalence of non-adherence to antihypertensive medication in Asia: a systematic review and meta-analysis.

Sajid Mahmood1, Zahraa Jalal2, Muhammad Abdul Hadi2, Tahir Mehmood Khan3, M Sayeed Haque4, Kifayat Ullah Shah5.   

Abstract

Background Hypertension and its associated complications are one of the leading causes of morbidity and mortality in Asia. Racial disparities in terms of treatment outcomes among hypertension patients have been reported in literature with Asian patients resulting in poorer treatment outcomes. Non-adherence to antihypertensive therapy is frequently associated with poor treatment outcomes. Aim of the review The aim of this review was to estimate the prevalence of non-adherence to antihypertensive medications among patients with hypertension residing in Asia. Method PubMed, Google Scholar, MEDLINE, Embase, Scopus, CINHAL and Cochrane library were searched for studies published between 2000 and 2019 involving hypertensive patients. Studies investigating the prevalence of medication non-adherence in Asian countries, rated either good or fair on National Institute of Health quality assessment tool and published in English language were included in our review. Data were extracted by one author and checked by another using a structured and pilot-tested data extraction sheet. A random-effects meta-analysis was performed using STATA version 14.3®. Results Sixty-Six studies from 22 Asian countries including 2,532,582 hypertensive patients were included. Mean (± SD) age of participants was 58(± 6) years. Overall, the estimated prevalence of non-adherence to antihypertensive medication in Asia was 48% (95% CI: 41-54, P = 0.001). The rate of non-adherence was higher among females 49% (95% CI: 41-56, P = 0.001) compared to males 47% (95% CI: 40-53, P = 0.001). As per the region, the highest prevalence of non-adherence was found in South Asia 48% (95% 44-51, P = 0.877) followed by East Asia 45% (31-59, P = 0.001) and the Middle East 41 (95% 30-52, P = 0.001). Similarly, higher rate of non-adherence was observed in low and lower middle-income countries i.e. 50% (95% CI: 47-54, P = 0.220) as compare to upper-middle and high-income countries i.e. 37% (95% CI: 25-49, P = 0.001) and 44% (95% CI: 29-59, P = 0.001) respectively. Conclusion The prevalence of non-adherence to antihypertensive medication is high in Asia. This may partly explain poor treatment outcomes and incidence of higher mortality rate in Asia frequently reported in the literature. There is a need to implement appropriate policies and clinical practices to improve medication adherence.

Entities:  

Keywords:  Asia; Compliance; Drug therapy; Hypertension; Systematic review

Year:  2021        PMID: 33515135     DOI: 10.1007/s11096-021-01236-z

Source DB:  PubMed          Journal:  Int J Clin Pharm


  44 in total

1.  Hypertension in Pakistan: time to take some serious action.

Authors:  Fahad Saleem; Jalan Sungai Dua; Azmi Ahmad Hassali; Asrul Akmal Shafie
Journal:  Br J Gen Pract       Date:  2010-06       Impact factor: 5.386

Review 2.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

3.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

4.  Application of the health belief model to improve the understanding of antihypertensive medication adherence among Chinese patients.

Authors:  Zhao Yue; Chen Li; Qi Weilin; Wang Bin
Journal:  Patient Educ Couns       Date:  2015-02-19

5.  Determinants of medication adherence and blood pressure control among hypertensive patients in Hong Kong: a cross-sectional study.

Authors:  Candy D Kang; Prilla P M Tsang; Winson T L Li; Harry H X Wang; Kirin Q L Liu; Sian M Griffiths; Martin C S Wong
Journal:  Int J Cardiol       Date:  2014-12-23       Impact factor: 4.164

6.  The healthcare burden of hypertension in Asia.

Authors:  Chun-Na Jin; Cheuk-Man Yu; Jing-Ping Sun; Fang Fang; Yong-Na Wen; Ming Liu; Alex Pui-Wai Lee
Journal:  Heart Asia       Date:  2013-11-19

Review 7.  Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice.

Authors:  K C Farmer
Journal:  Clin Ther       Date:  1999-06       Impact factor: 3.393

Review 8.  Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects.

Authors:  J Ø Nielsen; A D Shrestha; D Neupane; P Kallestrup
Journal:  J Hum Hypertens       Date:  2016-06-16       Impact factor: 3.012

9.  Adherence to cardiovascular medications in the South Asian population: A systematic review of current evidence and future directions.

Authors:  Julia M Akeroyd; Winston J Chan; Ayeesha K Kamal; Latha Palaniappan; Salim S Virani
Journal:  World J Cardiol       Date:  2015-12-26

10.  Adherence to Antihypertensives in Patients With Comorbid Condition.

Authors:  Zahra Saadat; Farahnaz Nikdoust; Hossein Aerab-Sheibani; Mostafa Bahremand; Elham Shobeiri; Habibollah Saadat; Yashar Moharramzad; Donald E Morisky
Journal:  Nephrourol Mon       Date:  2015-07-30
View more
  2 in total

1.  Effectiveness and Acceptability of a Mobile Phone Text Messaging Intervention to Improve Blood Pressure Control (TEXT4BP) among Patients with Hypertension in Nepal: A Feasibility Randomised Controlled Trial.

Authors:  Buna Bhandari; Padmanesan Narasimhan; Rohan Jayasuriya; Abhinav Vaidya; Aletta E Schutte
Journal:  Glob Heart       Date:  2022-02-23

2.  Community-based medication delivery program for antihypertensive medications improves adherence and reduces blood pressure.

Authors:  Dan N Tran; Kibet Kangogo; James A Amisi; James Kamadi; Rakhi Karwa; Benson Kiragu; Jeremiah Laktabai; Imran N Manji; Benson Njuguna; Daria Szkwarko; Kun Qian; Rajesh Vedanthan; Sonak D Pastakia
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.